Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | TRPV1 | Q8NER1 | 10/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | PDE4A | P27815 | 1/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5109897 | 0.88 | RAB9A (0.50) | LMNATRPV1KMT2ANPC1RAB9A | |
| SCHEMBL14421732 | 0.84 | TRPV1 (0.45) | LMNATRPV1KMT2A | |
| SCHEMBL5108222 | 0.84 | TRPV1 (0.45) | LMNATRPV1KMT2A | |
| SCHEMBL13613632 | 0.84 | LMNA (0.54) | LMNATRPV1KMT2AMTNR1AMTNR1B | |
| SCHEMBL5111558 | 0.83 | TRPV1 (0.49) | LMNATRPV1 | |
| SCHEMBL5118025 | 0.83 | TRPV1 (0.49) | LMNATRPV1 | |
| SCHEMBL5105662 | 0.83 | TRPV1 (0.49) | LMNATRPV1 | |
| SCHEMBL5558143 | 0.83 | TRPV1 (0.46) | LMNATRPV1RAB9A | |
| SCHEMBL5109705 | 0.81 | TRPV1 (0.43) | LMNATRPV1KMT2ARAB9A | |
| SCHEMBL13613647 | 0.80 | GAA (0.56) | LMNATRPV1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7423175-B2 | Hydroxy-tetrahydro-naphthalenylurea derivatives | BAYER HEALTHCARE AG (DE) | 2008-09-09 | — | — | US | claimed |
| EP-1594836-B1 | HYDROXY-TETRAHYDRO-NAPHTHALENYLUREA DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2007-09-19 | — | — | EP | claimed |
| US-20070027187-A1 | Hydroxy-tetrahydro-naphthalenylurea derivatives | BAYER HEALTHCARE AG (DE) | 2007-02-01 | — | — | US | claimed |
| EP-1594836-A1 | HYDROXY-TETRAHYDRO-NAPHTHALENYLUREA DERIVATIVES | Bayer HealthCare AG (DE) | 2005-11-16 | — | — | EP | claimed |
| WO-2004072020-A1 | HYDROXY-TETRAHYDRO-NAPHTHALENYLUREA DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2004-08-26 | — | — | WO | claimed |
| US-7423175-B2 | Hydroxy-tetrahydro-naphthalenylurea derivatives | BAYER HEALTHCARE AG (DE) | 2008-09-09 | — | — | US | disclosed |
| US-7423175-B2 | Hydroxy-tetrahydro-naphthalenylurea derivatives | BAYER HEALTHCARE AG (DE) | 2008-09-09 | — | — | US | disclosed |
| US-7423175-B2 | Hydroxy-tetrahydro-naphthalenylurea derivatives | BAYER HEALTHCARE AG (DE) | 2008-09-09 | — | — | US | disclosed |
| EP-1594836-B1 | HYDROXY-TETRAHYDRO-NAPHTHALENYLUREA DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2007-09-19 | — | — | EP | disclosed |
| EP-1594836-B1 | HYDROXY-TETRAHYDRO-NAPHTHALENYLUREA DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2007-09-19 | — | — | EP | disclosed |
| US-20070027187-A1 | Hydroxy-tetrahydro-naphthalenylurea derivatives | BAYER HEALTHCARE AG (DE) | 2007-02-01 | — | — | US | disclosed |
| US-20070027187-A1 | Hydroxy-tetrahydro-naphthalenylurea derivatives | BAYER HEALTHCARE AG (DE) | 2007-02-01 | — | — | US | disclosed |
| US-20070027187-A1 | Hydroxy-tetrahydro-naphthalenylurea derivatives | BAYER HEALTHCARE AG (DE) | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027187-A1 | Hydroxy-tetrahydro-naphthalenylurea derivatives | HVCN1, NMUR1, OPRL1 | LMNA 3474/4885TRPV1 31/4885KMT2A 3538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.